Endogenous Cushing’s Syndrome Therapeutics Market | 2032

Report Description

Endogenous Cushing’s Syndrome Therapeutics Market Outlook 2032 

The global endogenous Cushing’s syndrome therapeutics market size was USD 127.7 Million in 2023 and is likely to reach USD 291.5 Million by 2032, expanding at a CAGR of 9.6% during 2024–2032. The market growth is attributed to the increasing prevalence of Cushing’s disease.

Endogenous Cushing's syndrome arises when your body produces too much of the hormone cortisol. This excess disrupts various bodily functions, leading to a range of symptoms. According to the National Center for Biotechnology Information, endogenous Cushing’s syndrome accounts for 60% to 80% of all cases of Cushing’s syndrome globally.

Cushing's syndrome is managed with established therapies such as steroidogenesis inhibitors, adrenolytic agents, and glucocorticoid receptor antagonists. These medications suppress cortisol production in the adrenal glands and offer symptom relief. However, the market is witnessing the development of novel, targeted therapies with less side effects, offering personalized treatment options.

Several late-stage pipeline therapies are in development, with potential approvals that expected in the coming years. These therapies target different aspects of the disease pathway, offering promise for improved efficacy and less side effects.

Get Free Sample Report

Impact of Artificial Intelligence (AI) in Endogenous Cushing’s Syndrome Therapeutics Market

Artificial Intelligence (AI) has the potential to significantly impact the Cushing's syndrome therapeutics market by enhancing drug discovery, identifying novel drug targets, virtual drug screening, and predictive modeling. AI algorithms analyze vast datasets, virtually screen millions of potential drugs, and prioritize promising candidates for clinical trials.

AI algorithms improve diagnosis and treatment selection by analyzing medical images, recommending personalized treatments based on individual needs, and strategizing risk based on patient data, potentially reducing complications from Cushing's syndrome or potential side effects.

Endogenous Cushing’s Syndrome Therapeutics Market Dynamics

Get Free Sample Report

Major Drivers

Increasing awareness of Cushing’s syndrome and development of target therapies is expected to drive the global market. The development of targeted therapies that address specific aspects of the disease pathway, such as steroidogenesis inhibitors and cortisol receptor antagonists, offers personalized and potentially effective treatment options.

Existing Restraints

Limited options of medicines and side effects is expected to restrain the market during the forecast period. Existing therapies have significant side effects, and there is a lack of curative options. With only a handful of treatment options available, the market is restricted to patients who can tolerate and benefit from those specific medications. This limits the overall patient pool that can be treated, thus hindering the market.

Emerging Opportunities

Increasing focus on targeted therapies and biomarker identification for different subtypes of Cushing’s syndrome is expected to provide high opportunities in the market. Identifying biomarkers for different Cushing's syndrome subtypes allows for targeted treatment approaches based on individual patient needs. Development of accurate and non-invasive diagnostic tests is expected to facilitate early detection and improve patient outcomes.

Scope of the Endogenous Cushing’s Syndrome Therapeutics Market Report

The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Endogenous Cushing’s Syndrome Therapeutics Market Segment Insights

Drug Class Segment Analysis

Based on drug class, the market is divided into 11-Beta-Hydroxylase inhibitor and adrenal steroid inhibitors. The adrenal steroid inhibitors segment is expected to expand at a significant CAGR during the projection period, as it is the most common option for treatment. Moreover, the affordability of these drugs with sufficient efficacy is expected to fuel the segment during the forecast period. The wide availability of treatment and in many countries is increasing the accessibility of endogenous Cushing’s syndrome therapeutics and driving the segment.

The 11-Beta-Hydroxylase inhibitor segment is expected to hold a significant share of the market in the coming years, as 11β-Hydroxylase (CYP11B1) is considered as an attractive target for treating the diseases. Furthermore, 11β-Hydroxylase is a key enzyme responsible for the last step in cortisol biosynthesis, thus driving the segment. Inhibitors such as, steroidogenesis blockers are CYP11B1 inhibitors are frequently getting utilized. Recent advancements in reducing the side effects of these drugs are overcoming the limitations and hence, is anticipated to boost the segment during the forecast period.

Get Free Sample Report

Distribution Channel Segment Analysis

On the basis of distribution channel, the global market is segregated into hospitals pharmacy, retail pharmacy, online pharmacy. The hospital pharmacy segment is anticipated to expand at a considerable CAGR in the coming years due to the wide availability of specialized drug. Hospital pharmacies are well-equipped and has skilled staffs, providing proper explanation of dosage and side effects are expected to boost the segment.
 
The retail pharmacies segment is expected to expand at a significant CAGR during the forecast period. The ease in availability for varied medications and treatment options nearby is increasing the convenience and accessibility. Furthermore, the wide range of services is boosting the segment. Many retail pharmacies offer additional services beyond dispensing medications. This includes vaccinations, medication reviews, basic health screenings, and over-the-counter medication sales.

Get Free Sample Report

Regional Analysis

In terms of region, the global endogenous Cushing’s syndrome therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period owing to the high prevalence of endogenous Cushing’s disease. Additionally, the advanced healthcare system and well-equipped infrastructure is propelling the regional market. According to the National Organization for Rare Disorders, the incidence rate of endogenous Cushing’s syndrome is approximately 13 per million people annually in the US. Furthermore, many government and private organizations are taking initiative to get sponsors for the clinical trials of endogenous Cushing’s syndrome drug.

• In September 2023, Food and Drug Administration, in the US, released a draft entitled Endogenous Cushing’s Syndrome: Developing Drugs for Treatment for industrial guidance and provide recommendations to sponsor for clinical trials of drugs intended for the treatment of adults with endogenous Cushing’s syndrome for whom surgery is not an option or has not been curative.

Asia Pacific is expected to hold a large share during the forecast period due to increasing awareness and diagnosis for endogenous Cushing's syndrome among healthcare professionals and the general population in Asia Pacific. Improved diagnostic techniques and increased screening efforts contribute to early detection and diagnosis of the condition, leading to a large patient pool seeking treatment. Moreover, rising healthcare expenditure is expected to boost the market in the region. Many countries in Asia Pacific are experiencing economic growth, leading to increased healthcare spending. This results in improved access to healthcare services, including diagnosis and treatment for rare conditions like Cushing's syndrome.

Get Free Sample Report